Nl-Fr

View abstract

This abstract is assigned to session Free Papers - Oral Presentations II
Presentation preference Oral presentation
TitleRetreatment Criteria in Fluocinolone Acetonide implant treated Non-Infectious Uveitis (NIU)
Accept poster if oral is not possible ?Yes
PurposeFluocinolone acetonide implant (FAc, 0.2mg/day, ILUVIEN®) is licenced in the UK for the prevention of uveitis recurrence. We report the results in the largest single-centre cohort of eyes with NIU treated with FAc, allowing real-world evaluation of safety and efficacy focusing on retreatment criteria.
MethodsPatients treated with FAc for NIU between November 2019 and March 2021 were identified using a standardised audit tool. Parameters; demographics, type & severity of uveitis, best corrected visual acuity (BCVA, LogMAR), intraocular pressure (IOP, mmHg) central macula thickness (CMT, mm) and number and type of adjunctive treatments.
Results161 injected eyes had full 3 year plus follow-up available for analysis. In 86% Uveitic macula edema (UME) was treatment indication.
At baseline 98 eyes were pseudophakic, with 56 (89%) becaming pseudophakic during follow-up. Mean IOP remained 12-13mmHg
with 9 eyes (5.6%) having filtering surgery to control IOP.

After 3 years, 90 eyes (56%) had a sustained decrease in CMT and needed no further intervention. 19 eyes (12%) needed early and ongoing adjunctive dexamethasone (Ozurdex®) injections. 40 eyes (25%) had a partial response.
ConclusionILUVIEN® FAc implants have proven to be safe and efficacious over a 3 year period. This is the largest single-centre cohort of NIU patients treated with FAc.

25% of the eyes treated had a partial response that included those with waning effect and retreatment between years 2 to 3.
Using such measures of qualified success the overall rate of efficacy was 81%.
The primary indication to treat is UME, IOP rises were controlled. Of note 89% of phakic patients had cataract surgery within 3 years.
Conflict of interestYes
Details of conflicting interestsAlimera Sciences - Consultant
1
Last nameTUCKER
Initials of first name(s)W
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
2
Last namePAVESIO
Initials of first name(s)C
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
3
Last nameTESTI
Initials of first name(s)I
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
4
Last nameREES
Initials of first name(s)A
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
5
Last nameWESTCOTT
Initials of first name(s)M
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
6
Last namePETRUSHKIN
Initials of first name(s)H
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
7
Last nameCHU
Initials of first name(s)C
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
8
Last nameGURBAXANI
Initials of first name(s)A
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom
9
Last nameADDISON
Initials of first name(s)P
DepartmentMoorfields Eye Hospital NHS Foundation Trust
CityLondon
CountryUnited Kingdom